--- name: assessing-drug-interactions language: en description: Identifies clinically significant drug-drug, drug-food, and drug-disease interactions with severity grading and management recommendations. Use when checking drug interactions, evaluating polypharmacy risks, or managing medication combinations. tags: - assessment - pharmacy - risk - clinical metadata: author: casemark practice_areas: - Clinical Pharmacy - Pharmacy document_types: - Assessment Report skill_modes: - Assessment --- # Assessing Drug Interactions Identifies clinically significant drug-drug, drug-food, and drug-disease interactions with severity grading and management recommendations. ## Why This Skill Exists Drug interactions account for approximately 3-5% of all in-hospital medication errors and are a leading cause of preventable adverse drug events. The clinical consequences range from therapeutic failure (e.g., reduced efficacy of oral contraceptives with rifampin) to life-threatening toxicity (e.g., serotonin syndrome from SSRI-MAOI combinations, QT prolongation from concurrent QTc-prolonging agents). Polypharmacy patients—particularly elderly individuals on 5+ medications—face exponentially increasing interaction risk. Pharmacists are the final safety net before a drug reaches the patient. Robust interaction assessment requires knowledge of cytochrome P450 enzyme systems (CYP3A4, CYP2D6, CYP2C19, CYP1A2), P-glycoprotein transport, renal tubular secretion competition, and pharmacodynamic synergism/antagonism. Regulatory bodies including the Joint Commission (NPSG.03.05.01) and CMS Conditions of Participation mandate prospective drug utilization review for every dispensed prescription. Failure to identify a clinically significant interaction constitutes a deviation from the standard of care and carries malpractice liability. --- ## Checkpoint A: Pre-Draft Intake (Mandatory) 1. What is the complete active medication list, including OTC, herbals, and supplements? (Default: request MAR or pharmacy profile) 2. What is the patient's age, sex, weight, and relevant organ function (hepatic/renal)? (Default: assume normal organ function if unspecified, flag as [VERIFY]) 3. What is the clinical indication for each medication under review? (Default: pull from problem list) 4. Is there a specific new medication being added, or is this a comprehensive polypharmacy review? (Default: comprehensive) 5. What interaction databases are available? (Default: Lexicomp, Clinical Pharmacology, Micromedex) 6. Are there known patient-specific sensitivities or prior ADR history? (Default: none documented) 7. What is the care setting—inpatient, outpatient, or transitions of care? (Default: inpatient) 8. Is pharmacogenomic data available (CYP2D6, CYP2C19 phenotype)? (Default: not available) ### Documents to Request - Current medication administration record (MAR) or e-prescribing profile - Recent lab values: INR, serum drug levels, LFTs, SCr/BUN, electrolytes (K+, Mg2+, QTc if relevant) - Pharmacogenomic panel results if available - Allergy and ADR history - Problem list with active diagnoses - Recent ECG if QTc-prolonging agents are involved --- ## Step 1: Catalog All Active Substances List every active pharmaceutical ingredient the patient is receiving. Include: - Prescription medications with dose, route, frequency - OTC medications (NSAIDs, antihistamines, PPIs) - Herbal/dietary supplements (St. John's wort, grapefruit, ginkgo) - PRN medications and recent as-needed use dates Assign each substance its primary metabolic pathway: | CYP Enzyme | Common Substrates | Common Inhibitors | Common Inducers | |---|---|---|---| | CYP3A4 | Simvastatin, cyclosporine, midazolam | Ketoconazole, clarithromycin, ritonavir | Rifampin, phenytoin, carbamazepine | | CYP2D6 | Codeine, metoprolol, fluoxetine | Paroxetine, fluoxetine, bupropion | Not significantly inducible | | CYP2C19 | Clopidogrel, omeprazole, voriconazole | Fluconazole, fluvoxamine, omeprazole | Rifampin, St. John's wort | | CYP2C9 | Warfarin, phenytoin, losartan | Fluconazole, amiodarone, metronidazole | Rifampin | | CYP1A2 | Theophylline, clozapine, caffeine | Fluvoxamine, ciprofloxacin | Smoking, omeprazole (minor) | --- ## Step 2: Screen and Classify Interactions Run each combination through at least two independent drug interaction databases. Classify each identified interaction: **Severity Grading (use Lexicomp/Micromedex concordance):** - **Contraindicated (X):** Combination must not be used. Examples: linezolid + serotonergic agents, simvastatin + itraconazole - **Major (D):** Modify therapy; combination may cause serious harm. Examples: warfarin + fluconazole, methotrexate + trimethoprim - **Moderate (C):** Monitor therapy; adjust dose or timing as needed. Examples: ACE inhibitors + potassium supplements, digoxin + amiodarone - **Minor (B):** No action needed for most patients. Examples: antacids + iron timing **Mechanism Classification:** - Pharmacokinetic: absorption, distribution, metabolism (CYP inhibition/induction), elimination - Pharmacodynamic: additive, synergistic, or antagonistic effects at receptor/organ level - Mixed: both PK and PD components --- ## Step 3: Evaluate Clinical Significance Not all flagged interactions require intervention. Assess clinical significance by: 1. **Therapeutic index:** Narrow therapeutic index drugs (warfarin, digoxin, lithium, phenytoin, theophylline, aminoglycosides) demand higher vigilance 2. **Onset timing:** Immediate (within 24 hours) vs. delayed (days to weeks, e.g., enzyme induction) 3. **Dose-dependency:** Some interactions only manifest at higher doses (e.g., QTc prolongation) 4. **Patient vulnerability:** Age >65, hepatic/renal impairment, genetic polymorphisms increase risk 5. **Duration of co-administration:** Short-term concurrent use may not reach steady-state interaction 6. **Evidence quality:** Case reports vs. controlled studies vs. mechanistic extrapolation --- ## Step 4: Formulate Management Recommendations For each clinically significant interaction, provide one of: - **Avoid combination:** Recommend specific therapeutic alternative - **Dose adjustment:** Specify percentage reduction or new target dose - **Enhanced monitoring:** Define parameters (lab values, vital signs, symptoms) and frequency - **Timing separation:** Specify administration interval (e.g., fluoroquinolones and cations separated by 2 hours) - **Patient counseling points:** Symptoms to watch for and when to seek care Document the supporting evidence level for each recommendation (clinical guideline, pharmacokinetic study, case series, or mechanistic rationale). --- ## Step 5: Generate Interaction Assessment Report Structure the final output as: 1. **Patient identifier and date of review** 2. **Interaction summary table:** Drug pair | Severity | Mechanism | Recommendation | Evidence level 3. **Detailed narrative for each Major/Contraindicated interaction** 4. **Monitoring plan with timeline** 5. **Medications cleared with no significant interactions** 6. **Pharmacist attestation and limitations statement** --- ## Checkpoint B: Post-Draft Alignment (Mandatory) 1. Were all active medications including OTC/herbals accounted for in the screen? 2. Do severity ratings from the two databases agree, and were discrepancies resolved? 3. Has each Major or Contraindicated interaction received a specific management recommendation? 4. Are monitoring parameters clearly defined with lab/timing specifics? 5. Have narrow therapeutic index drugs been individually addressed regardless of screen results? --- ## Quality Audit - [ ] Complete medication list was obtained and documented - [ ] At least two independent interaction databases were queried - [ ] Each interaction is classified by severity (X, D, C, B) and mechanism (PK, PD, mixed) - [ ] Contraindicated combinations have clear stop-or-substitute directives - [ ] Narrow therapeutic index drugs were individually reviewed - [ ] CYP enzyme pathways are cited for pharmacokinetic interactions - [ ] Pharmacogenomic status is addressed if data available - [ ] Monitoring parameters include specific lab values, intervals, and escalation triggers - [ ] Timing-sensitive interactions include administration scheduling guidance - [ ] Patient-specific risk factors (age, organ function) are factored into significance assessment - [ ] Evidence level is cited for each recommendation - [ ] Report includes limitations and [VERIFY] flags for missing data - [ ] QTc-prolonging combinations are flagged with ECG monitoring recommendation --- ## Guidelines - Always screen against at least two interaction databases to reduce false negatives - Classify by mechanism (PK vs. PD) before grading severity—mechanism informs management - Prioritize narrow therapeutic index drugs for detailed review regardless of initial screen - Never dismiss a contraindicated (X-rated) interaction without prescriber communication and documentation - Include OTC and herbal products; St. John's wort is a potent CYP3A4/P-gp inducer often missed - Factor in pharmacogenomic status when available—CYP2D6 poor metabolizers face amplified inhibition interactions - Document clinical rationale when accepting a moderate interaction with monitoring rather than avoidance - Time-stamp all assessments; interaction profiles change when medications are added or discontinued